del Amo Eva M, Urtti Arto, Yliperttula Marjo
Centre for Drug Research, University of Helsinki, Helsinki, Finland.
Eur J Pharm Sci. 2008 Oct 2;35(3):161-74. doi: 10.1016/j.ejps.2008.06.015. Epub 2008 Jul 5.
LAT1 and LAT2 are heterodimeric large amino acid transporters that are expressed in various tissues, including the intestinal wall, blood-brain barrier, and kidney. These transporters consist of membrane spanning light chain and heavy chain, and they act as 1:1 exchangers in concert with other amino acid transporters. Only a few drugs (less than 10) are substrates of LAT1 and LAT2, including L-DOPA, alpha-methyldopa, melphalan, and gabapentin. The mechanisms and substrates have been mostly elucidated using mammalian cells and Xenopus oocytes. The in vivo relevance of LAT1 and LAT2 in pharmacokinetics is obscure, because contradictory findings have been reported. It is difficult to make quantitative pharmacokinetic conclusions about LAT1 and LAT2. This is due to the possible involvement of other transporters (including cross-linked heterodimers of light chain with different heavy chains, other overlapping transporters, for example TAT1), competing endogenous amino acids, and saturation phenomena. This review presents the current functional knowledge on LAT1 and LAT2 with emphasis on their potential involvement in pharmacokinetics.
LAT1和LAT2是异二聚体大氨基酸转运体,在包括肠壁、血脑屏障和肾脏在内的多种组织中表达。这些转运体由跨膜轻链和重链组成,它们与其他氨基酸转运体协同作用,作为1:1的交换体。只有少数几种药物(不到10种)是LAT1和LAT2的底物,包括左旋多巴、α-甲基多巴、美法仑和加巴喷丁。其机制和底物大多是通过哺乳动物细胞和非洲爪蟾卵母细胞来阐明的。LAT1和LAT2在药代动力学中的体内相关性尚不明确,因为已有相互矛盾的研究结果报道。很难对LAT1和LAT2做出定量的药代动力学结论。这是由于可能涉及其他转运体(包括轻链与不同重链的交联异二聚体、其他重叠的转运体,例如TAT1)、竞争性内源性氨基酸以及饱和现象。本综述介绍了目前关于LAT1和LAT2的功能知识,重点强调了它们在药代动力学中的潜在作用。